Aisling Capital’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Aisling Capital’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-3,855	Closed	-$34K	–	23
2015 Q4	$34K	Sell	3,855 -350,000	-99%	-$2.95M	0.01%	22
2015 Q3	$2.97M	Sell	353,855 -1,350,000	-79%	-$21.5M	0.52%	20
2015 Q2	$30M	Sell	1,703,855 -59,645	-3%	-$766K	4.47%	9
2015 Q1	$20.4M	Hold	1,763,500	–	–	2.67%	14
2014 Q4	$17.8M	Hold	1,763,500	–	–	2.69%	14
2014 Q3	$7.97M	Hold	1,763,500	–	–	1.55%	15
2014 Q2	$11.9M	Buy	1,763,500 +1,142,800	+184%	+$8.62M	3.44%	10
2014 Q1	$8M	Hold	620,700	–	–	5.56%	5
2013 Q4	$5M	Buy	+620,700	New	+$5.46M	3.06%	6

Other funds holding SRNE

WCM

Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Aisling Capital's SRNE Position: Q1 2016 in Review

Aisling Capital sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2016, closing a stake of 3,855 shares — an estimated $34K sold.

Aisling Capital first reported a position in SRNE in Q4 2013 and held it in 9 quarters. The position peaked at $30M in Q2 2015. 68 funds tracked by Wall St. Rank hold SRNE as of Q1 2016.

Aisling Capital reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2016 after selling out during the quarter.
Aisling Capital sold 3,855 Sorrento Therapeutics, Inc. shares in Q1 2016, an estimated $34K.
Aisling Capital first reported a position in Sorrento Therapeutics, Inc. in Q4 2013 and held it in 9 quarters.
Aisling Capital's Sorrento Therapeutics, Inc. position peaked at $30M in Q2 2015.
68 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2016.

Based on Aisling Capital's 13F filing for Q1 2016, filed 13 May 2016.